Cinepazide maleate
Alternative Names: Anjieli; KelinaoLatest Information Update: 02 Oct 2021
At a glance
- Originator Sihuan Pharmaceutical Holdings Group
- Class Antiparkinsonians; Neuroprotectants; Peripheral vasodilators
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ischaemia
Most Recent Events
- 31 Oct 2012 Sihuan Pharmaceutical initiates a post-marketing surveillance trial in Chinese patients (NCT01946919; PACER)